Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Microbial Issues

Predictors of invasive fungal infection in pediatric allogeneic hematopoietic SCT recipients

Bone Marrow Transplantation volume 49, pages 95–101 (2014)Cite this article

Subjects

Abstract

This study was aimed at finding predictors of invasive fungal infection (IFI) after pediatric allogeneic hematopoietic SCT (HSCT). All children who received allogeneic HSCT in the Wilhelmina Children’s Hospital Utrecht between 2004 and 2012 were included. HSCT data were prospectively collected. Patients were retrospectively classified into high- or low-risk groups for developing IFI using criteria based on available literature. Predictors for the occurrence of IFI were analyzed using Cox regression models. We used logistic regression models to analyze the association between other HSCT-related complications and IFI. Secondary outcomes were overall survival and treatment-related mortality (TRM). Two-hundred nine patients were included in the analysis; median age was 6.6 years. The cumulative incidence of IFI was 12%. In patients classified as ‘low risk’ (n=75), only 5.3% developed IFI (odds ratio (OR): 0.325; P=0.047). In multivariate analysis, a predictor for the occurrence of IFI was an a priori determined HSCT TRM risk >20% (based on EBMT-risk score). Post-HSCT, the administration of high-dose steroids was associated with IFI (OR: 4.458; P=0.010). Patients who developed IFI showed an increased risk of TRM (OR: 3.773; P=0.004). These results confirm that risk group stratification should guide intensity of monitoring for IFI and use of antifungal prophylaxis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Dvorak CC, Steinbach WJ, Brown JMY, Agarwal R . Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2005; 36: 621–629.

    Article  CAS  PubMed  Google Scholar 

  2. Kobayashi R, Kaneda M, Sato T, Suzuki D, Ichikawa M, Ariga T . Evaluation of risk factors for invasive fungal infection after allogeneic stem cell transplantation in pediatric patients. J Pediatr Hematol Oncol 2007; 29: 786–791.

    Article  PubMed  Google Scholar 

  3. Kobayashi R, Kaneda M, Sato T, Ichikawa M, Suzuki D, Ariga T . The clinical feature of invasive fungal infection in pediatric patients with hematologic and malignant diseases: a 10-year analysis at a single institution at Japan. J Pediatr Hematol Oncol 2008; 30: 886–890.

    Article  PubMed  Google Scholar 

  4. Hovi L, Saarinen-Pihkala UM, Vettenranta K, Saxen H . Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years. Bone Marrow Transplant 2000; 26: 999–1004.

    Article  CAS  PubMed  Google Scholar 

  5. Benjamin DK Jr, Miller WC, Bayliff S, Martel L, Alexander KA, Martin PL . Infections diagnosed in the first year after pediatric stem cell transplantation. Pediatr Infect Dis J 2002; 21: 227–234.

    Article  PubMed  Google Scholar 

  6. Crassard N, Hadden H, Pondarre C, Hadden R, Galambrun C, Piens MA et al. Invasive aspergillosis and allogeneic hematopoietic stem cell transplantation in children: a 15-year experience. Transpl Infect Dis 2008; 10: 177–183.

    Article  CAS  PubMed  Google Scholar 

  7. Mikulska M, Raiola AM, Bruno B, Furfaro E, Van Lint MT, Bregante S et al. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients. Bone Marrow Transplant 2009; 44: 361–370.

    Article  CAS  PubMed  Google Scholar 

  8. Srinivasan A, Wang C, Srivastava DK, Burnette K, Shenep JL, Leung W et al. Timeline, epidemiology, and risk factors for bacterial, fungal, and viral infections in children and adolescents after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012 pii S1083-8791: 00334–00335.

    Google Scholar 

  9. Marr KA, Carter RA, Crippa F, Wald A, Corey L . Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909–917.

    Article  PubMed  Google Scholar 

  10. Barnes PD, Risks Marr KA . Diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients. Br J Haematol 2007; 139: 519–531.

    Article  PubMed  Google Scholar 

  11. Castagnola E, Faraci M, Moroni C, Bandettini R, Granata C, Caruso S et al. Invasive mycoses in children receiving hemopoietic SCT. Bone Marrow Transplant 2008; 41: S107–S111.

    Article  PubMed  Google Scholar 

  12. Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010 15 50: 1091–1100.

    Article  PubMed  Google Scholar 

  13. Kontoyiannis DP . Antifungal prophylaxis in hematopoietic stem cell transplant recipients: the unfinished tale of imperfect success. Bone Marrow Transplant 2011; 46: 165–173.

    Article  CAS  PubMed  Google Scholar 

  14. Rogers TR, Slavin MA, Donnelly JP . Antifungal prophylaxis during treatment for haematological malignancies: are we there yet? Br J Haematol 2011; 153: 681–697.

    Article  PubMed  Google Scholar 

  15. Pauw de BE . What are fungal infections? Mediterr J Hematol Infect Dis 2011; 3: e2011001.

    Article  Google Scholar 

  16. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295–304.

    Article  CAS  PubMed  Google Scholar 

  17. Gratwohl A . The EBMT risk score. Bone Marrow Transplant 2012; 47: 749–756.

    Article  CAS  PubMed  Google Scholar 

  18. Pauw DeB, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T et al. Revised definitions of invasive fungal disease from European organisation for research and treatment of cancer/invasive fungal infections cooperative Group and the national institute of allergy and infectious diseases mycoses study Group (EORTC/MSG) concensus Group. Clin Infect Dis 2008; 46: 1813–1821.

    Article  PubMed  Google Scholar 

  19. Blyth CC, Hale K, Palasanthiran P, O'Brien T, Bennett MH . Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections. Cochrane Database Syst Rev 2010; 17 CD006343.

  20. Snelders E, van der Lee HA, Kuijpers J, Rijs AJ, Varga J, Samson RA et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 2008; 5: e219.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Bartelink IH, Wolfs T, Martine J, de Waal M, Egberts TC, Ververs TT et al. Immune reconstitution kinetics as an early predictor for mortality using various hematopoietic stem cell sources in children. Biol Blood Marrow Transplant 2012 22. pii S1083-8791: 00426–0.

    Google Scholar 

  22. Ram R, Gafter-Gvili A, Yeshurun M, Paul M, Raanani P, Shpilberg O . Prophylaxis regimens for GVHD: systematic review and meta-analysis. Bone Marrow Transplant 2009; 43: 643–653.

    Article  CAS  PubMed  Google Scholar 

  23. Ferrara JL, Levine JE, Reddy P, Holler E . Graft-versus-host disease. Lancet 2009; 373: 1550–1561.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Rocha V, Locatelli F . Searching for alternative hematopoietic stem cell donors for pediatric patients. Bone Marrow Transplant 2008; 41: 207–214.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatric Blood and Marrow Transplantation, University Medical Centre Utrecht (UMCU), Utrecht, The Netherlands

    J A Hol, T F W Wolfs, M B Bierings, C A Lindemans, A B J Versluys, A Wildt de, C E Gerhardt & J J Boelens

Authors
  1. J A Hol
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T F W Wolfs
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M B Bierings
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C A Lindemans
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A B J Versluys
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Wildt de
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C E Gerhardt
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J J Boelens
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J A Hol.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hol, J., Wolfs, T., Bierings, M. et al. Predictors of invasive fungal infection in pediatric allogeneic hematopoietic SCT recipients. Bone Marrow Transplant 49, 95–101 (2014). https://doi.org/10.1038/bmt.2013.136

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2013.136

Keywords

This article is cited by

Search

Advanced search

Quick links